Arrowhead Pharmaceuticals (ARWR) Retained Earnings (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Retained Earnings came in at -$1.7 billion in Q1 2026, down 39486.67% YoY from N/an in Q1 2025, and down 8.31% on a QoQ basis from -$1.6 billion in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Retained Earnings (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Retained Earnings data on file, last reported at -$1.7 billion in Q1 2026.
- Quarterly Retained Earnings fell 39486.67% year-over-year to -$1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 39486.67% YoY) and the FY2025 annual result came in at $6.4 million, up 100.4% from the prior year.
- Retained Earnings retreated to -$1.7 billion in Q1 2026, from -$1.6 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $6.4 million in Q3 2025 to a low of -$1.8 billion in Q4 2024.
- A 5-year average of -$671.6 million and a median of -$1.3 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings slumped 754333.82% — and 2025, when it jumped 100.4%.
- Tracing ARWR's Retained Earnings over 5 years: stood at -$258000.0 in 2022, then slumped by 386.43% to -$1.3 million in 2023, then tumbled by 143215.38% to -$1.8 billion in 2024, then increased by 11.25% to -$1.6 billion in 2025, then dropped by 8.31% to -$1.7 billion in 2026.
- The last three Retained Earnings figures came in at -$1.7 billion (Q1 2026), -$1.6 billion (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -1.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.92 Bn |
| Mar 31, 2026 | -1.73 Bn |
| Dec 31, 2025 | -1.60 Bn |
| Sep 30, 2025 | 6.44 Mn |
| Jun 30, 2025 | 5.36 Mn |
| Mar 31, 2025 | 4.39 Mn |
| Dec 31, 2024 | -1.80 Bn |
| Sep 30, 2024 | -1.63 Bn |
| Jun 30, 2024 | -1.45 Bn |
| Mar 31, 2024 | -1.28 Bn |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -1.03 Bn |
| Jun 30, 2023 | -916.35 Mn |
| Mar 31, 2023 | -332,000.00 |
| Dec 31, 2022 | -258,000.00 |
| Sep 30, 2022 | -136,000.00 |
| Jun 30, 2022 | -140,000.00 |
| Mar 31, 2022 | -107,000.00 |
| Dec 31, 2021 | -707.56 Mn |
| Sep 30, 2021 | -644.69 Mn |